The clinical impact of Pseudomonas aeruginosa eradication in bronchiectasis in a Dutch referral centre Source: Eur Respir J, 53 (4) 1802081; 10.1183/13993003.02081-2018 Year: 2019
The clinical impact of pseudomonas aeruginosa eradication in bronchiectasis in a Dutch center of expertise Source: International Congress 2018 – Bronchiectasis: phenotypes, endotypes and new therapies Year: 2018
Does a single Pseudomonas aeruginosa isolation predict COPD mortality? Source: Eur Respir J 2014; 44: 794-797 Year: 2014
Successful Pseudomonas aeruginosa eradication improves outcomes after lung transplantation: a retrospective cohort analysis Source: Eur Respir J, 56 (4) 2001720; 10.1183/13993003.01720-2020 Year: 2020
Pseudomonas aeruginosa in patients with cystic fibrosis - a comparison of early eradication and conventional therapySource: Eur Respir J 2004; 24: Suppl. 48, 385s Year: 2004
DNA fingerprinting of Pseudomonas aeruginosa (Pa) in cystic fibrosis patients: risk assessment of cross-colonisation in a CF revalidation centre Source: Eur Respir J 2002; 20: Suppl. 38, 208s Year: 2002
The independent contribution of Pseudomonas aeruginosa infection to long-term clinical outcomes in bronchiectasis Source: Eur Respir J, 51 (2) 1701953; 10.1183/13993003.01953-2017 Year: 2018
DNA fingerprinting of pseudomonas aeruginosa in cystic fibrosis patients: risk assessment of cross-infection in a CF centre Source: Eur Respir J 2002; 20: Suppl. 38, 208s Year: 2002
Can LCI predict new Pseudomonas aeruginosa colonization among CF patients?> Source: International Congress 2017 – What is the future for paediatric respiratory physiology and sleep? Year: 2017
Low transmission risk of Pseudomonas aeruginosa in a bronchiectasis clinic based on the knowledge of bacterial population biology Source: Eur Respir J, 53 (3) 1802191; 10.1183/13993003.02191-2018 Year: 2019
Pseudomonas aeruginosa in patients hospitalised for COPD exacerbation: a prospective study Source: Eur Respir J 2009; 34: 1072-1078 Year: 2009
Persistence and genetic adaptation of Pseudomonas aeruginosa in patients with COPD. Source: Virtual Congress 2020 – Airway infection: the microbiome and beyond Year: 2020
Cystic fibrosis infection with clonal strains of Pseudomonas aeruginosa: current knowledge and future management Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-46-6, page=105 Year: 2006
Pseudomonas aeruginosa DNA-fingerprinting of colonized CF-patients in a rehabilitation centre: a 2-years surveySource: Eur Respir J 2003; 22: Suppl. 45, 174s Year: 2003
Colonisation in stable patients with COPD: results of an Italian epidemiological study (PRIME study) Source: Annual Congress 2005 - Acute and chronic infections in COPD Year: 2005
Evaluating the Leeds criteria for Pseudomonas aeruginosa infection in a cystic fibrosis centre Source: Eur Respir J 2006; 27: 937-943 Year: 2006
Antibiotics reduce dual pathogen isolates more than single pathogen isolates following COPD exacerbation Source: Annual Congress 2009 - Exacerbations of COPD: new findings Year: 2009
The role of inhaled antibiotics in bronchial infection Source: Eur Respir Monogr 2013; 60: 120-126 Year: 2013
Influence of biofim on the bronchial microbiome in COPD patients colonized or infected by pseudomonas aeruginosa Source: International Congress 2015 – Advances from translational research in respiratory infections Year: 2015
COPD diagnosis and treatment in the primary care setting: adherence to GOLD guidelines is far away Source: Virtual Congress 2020 – Organising respiratory disease management in primary care Year: 2020